1. Pioglitazone and rosiglitazone are both PPAR-gamma (peroxisome proliferator-activated receptor gamma) agonists, yet they differ in their nuclear receptor activity. Which statement most precisely discriminates the receptor pharmacology of the two agents?
A) Rosiglitazone activates both PPAR-gamma and PPAR-alpha, while pioglitazone is PPAR-gamma-selective
B) Both agents are selective PPAR-alpha agonists with negligible PPAR-gamma activity
C) Pioglitazone activates both PPAR-gamma and, to a lesser degree, PPAR-alpha, while rosiglitazone is the more PPAR-gamma-selective agent
D) Pioglitazone is a PPAR-delta agonist, while rosiglitazone activates PPAR-gamma exclusively
E) The two agents are pharmacologically identical at the receptor level and differ only in potency
ANSWER: C
Rationale:
The precise discrimination is that pioglitazone activates both PPAR-gamma (peroxisome proliferator-activated receptor gamma) and, to a lesser degree, PPAR-alpha (peroxisome proliferator-activated receptor alpha, the hepatic lipid-oxidation receptor), whereas rosiglitazone is the more PPAR-gamma-selective agent. This added PPAR-alpha component is the mechanistic basis for pioglitazone's more favorable lipid profile.
Option A: Option A is incorrect because it reverses the two agents; it is pioglitazone, not rosiglitazone, that carries the additional PPAR-alpha activity.
Option B: Option B is incorrect because both agents are principally PPAR-gamma agonists, not selective PPAR-alpha agonists.
Option D: Option D is incorrect because pioglitazone is not a PPAR-delta agonist; its secondary activity is at PPAR-alpha.
Option E: Option E is incorrect because the two agents are not pharmacologically identical at the receptor level; the PPAR-alpha difference is precisely what distinguishes them.
2. Thiazolidinediones (TZDs) are metabolized chiefly by CYP2C8 (cytochrome P450 2C8). Which statement correctly describes the direction of the resulting drug interactions?
A) Gemfibrozil, a potent CYP2C8 inhibitor, increases TZD exposure, whereas rifampin, a CYP2C8 inducer, decreases it
B) Gemfibrozil induces CYP2C8 and lowers TZD exposure, whereas rifampin inhibits it and raises exposure
C) Both gemfibrozil and rifampin increase TZD exposure to a similar degree
D) Neither gemfibrozil nor rifampin alters TZD exposure because TZDs are not CYP-metabolized
E) Gemfibrozil and rifampin both decrease TZD exposure through enzyme induction
ANSWER: A
Rationale:
TZDs are CYP2C8 (cytochrome P450 2C8) substrates. Gemfibrozil is a potent CYP2C8 inhibitor and substantially increases pioglitazone and rosiglitazone exposure (area under the curve), raising adverse-effect risk, whereas rifampin is a CYP2C8 inducer and reduces TZD exposure.
Option B: Option B is incorrect because it inverts both relationships: gemfibrozil inhibits (not induces) and rifampin induces (not inhibits).
Option C: Option C is incorrect because the two agents act in opposite directions, not the same direction.
Option D: Option D is incorrect because TZDs are in fact CYP2C8-metabolized, so these interactions do occur.
Option E: Option E is incorrect because only rifampin induces; gemfibrozil inhibits and raises exposure, so they do not both decrease it.
3. The two principal incretin hormones are secreted by distinct enteroendocrine cell populations in different regions of the gut. Which pairing of hormone, cell type, and location is correct?
A) GLP-1 is secreted by K cells in the proximal duodenum; GIP is secreted by L cells in the distal ileum
B) Both GLP-1 and GIP are secreted by the same L cells distributed evenly along the entire small intestine
C) GIP is secreted by alpha cells of the pancreatic islet; GLP-1 is secreted by beta cells
D) GLP-1 (glucagon-like peptide-1) is secreted by L cells in the distal ileum and colon; GIP (glucose-dependent insulinotropic polypeptide) is secreted by K cells in the proximal duodenum and jejunum
E) GLP-1 and GIP are both secreted by K cells confined to the terminal colon
ANSWER: D
Rationale:
GLP-1 (glucagon-like peptide-1) is secreted by enteroendocrine L cells in the distal ileum and colon in response to nutrient ingestion, whereas GIP (glucose-dependent insulinotropic polypeptide) is secreted by K cells in the proximal duodenum and jejunum.
Option A: Option A is incorrect because it swaps the two: GLP-1 is the L-cell/distal hormone and GIP is the K-cell/proximal hormone, not the reverse.
Option B: Option B is incorrect because the two hormones arise from distinct cell types in different regions, not from a single uniformly distributed L-cell population.
Option C: Option C is incorrect because both incretins are gut-derived enteroendocrine hormones, not islet alpha- or beta-cell products.
Option E: Option E is incorrect because GLP-1 and GIP are not both K-cell products confined to the terminal colon; they have distinct cellular and regional origins.
4. DPP-4 (dipeptidyl peptidase-4) inhibitors and injectable GLP-1 (glucagon-like peptide-1) receptor agonists both act on the incretin axis, but produce different magnitudes of effect. Which statement most precisely distinguishes them?
A) DPP-4 inhibitors raise GLP-1 levels 5- to 8-fold, exceeding the elevation produced by GLP-1 receptor agonists
B) DPP-4 inhibitors produce a modest (approximately 2-fold) rise in endogenous incretin levels, whereas GLP-1 receptor agonists achieve a 5- to 8-fold elevation, explaining the larger HbA1c reduction and weight loss with agonists
C) Both drug classes produce identical incretin elevations and identical weight effects
D) GLP-1 receptor agonists produce a smaller incretin effect than DPP-4 inhibitors and therefore cause less weight loss
E) DPP-4 inhibitors cause substantial weight loss equal to that of GLP-1 receptor agonists
ANSWER: B
Rationale:
DPP-4 (dipeptidyl peptidase-4) inhibitors raise postprandial endogenous incretin concentrations only modestly (approximately 2-fold), whereas injectable GLP-1 (glucagon-like peptide-1) receptor agonists achieve a 5- to 8-fold elevation of GLP-1 activity. This magnitude difference explains why agonists produce larger HbA1c reductions (1.0 to 2.0 percent or greater) and significant weight loss, while gliptins produce more modest HbA1c reductions (0.5 to 1.0 percent) and are weight-neutral.
Option A: Option A is incorrect because it reverses the magnitudes; the 5- to 8-fold elevation belongs to the agonists, not to DPP-4 inhibitors.
Option C: Option C is incorrect because the two classes do not produce identical incretin elevations or weight effects.
Option D: Option D is incorrect because GLP-1 receptor agonists produce the larger, not smaller, incretin effect and therefore more weight loss.
Option E: Option E is incorrect because DPP-4 inhibitors are weight-neutral and do not produce weight loss equal to the agonists.
5. Within the DPP-4 (dipeptidyl peptidase-4) inhibitor class, cytochrome P450 metabolism differs by agent. Which statement correctly discriminates the class with respect to CYP3A4 (cytochrome P450 3A4)?
A) Sitagliptin is a CYP3A4 substrate requiring dose reduction with potent CYP3A4 inhibitors
B) Linagliptin is the only gliptin extensively metabolized by CYP3A4
C) All five gliptins are equally dependent on CYP3A4 for clearance
D) None of the gliptins interact with CYP3A4 under any circumstances
E) Saxagliptin is a CYP3A4 substrate requiring dose reduction with potent CYP3A4 inhibitors, whereas sitagliptin and linagliptin are not significantly metabolized by cytochrome P450 enzymes
ANSWER: E
Rationale:
Saxagliptin is a CYP3A4 (cytochrome P450 3A4) substrate, so a potent CYP3A4 inhibitor requires reducing its dose; in contrast, sitagliptin and linagliptin are not significantly metabolized by cytochrome P450 enzymes and have minimal interaction profiles.
Option A: Option A is incorrect because sitagliptin is not a meaningful CYP3A4 substrate; the CYP3A4 interaction belongs to saxagliptin.
Option B: Option B is incorrect because linagliptin is not extensively CYP3A4-metabolized; it is eliminated largely unchanged by the biliary/fecal route.
Option C: Option C is incorrect because the gliptins are not equally CYP3A4-dependent; only saxagliptin (and to some extent alogliptin) is relevant.
Option D: Option D is incorrect because saxagliptin clearly does interact with CYP3A4, so the blanket denial is wrong.
6. Acarbose and miglitol are both contraindicated in significant renal impairment, but for mechanistically different reasons. Which statement correctly discriminates the two?
A) Both acarbose and miglitol are extensively absorbed as parent drug and cleared by hepatic metabolism
B) Acarbose is contraindicated because renally excreted bacterial degradation products accumulate, whereas miglitol is contraindicated because it is substantially absorbed and renally excreted unchanged
C) Acarbose is well absorbed systemically while miglitol acts only in the gut lumen with no absorption
D) Neither drug is affected by renal function because both act exclusively in the intestinal lumen
E) Miglitol accumulates because of biliary excretion failure, whereas acarbose is cleared entirely by the liver
ANSWER: B
Rationale:
Acarbose has essentially no systemic absorption of parent drug (less than 2 percent), but bacterial degradation products formed in the colon are absorbed and renally excreted, so they accumulate in renal impairment, which is why acarbose is contraindicated. Miglitol, by contrast, is substantially absorbed (bioavailability roughly 50 to 70 percent at low doses) and excreted unchanged by the kidneys, making it contraindicated in significant renal impairment for that distinct reason.
Option A: Option A is incorrect because acarbose is not extensively absorbed as parent drug, and neither agent relies on hepatic metabolism for the contraindication.
Option C: Option C is incorrect because it reverses the absorption profiles: miglitol is the substantially absorbed agent, while acarbose acts largely in the lumen.
Option D: Option D is incorrect because both drugs are in fact affected by renal function, contrary to the claim of no renal relevance.
Option E: Option E is incorrect because miglitol accumulates through renal excretion of the unchanged drug, not biliary excretion failure, and acarbose is not cleared entirely by the liver.
7. The fluid retention caused by thiazolidinediones (TZDs) has a specific renal mechanism that distinguishes it from aldosterone-mediated sodium retention. Which statement is correct?
A) TZD fluid retention is driven by increased aldosterone secretion acting on the distal tubule
B) TZD fluid retention results from a rise in systemic blood pressure that drives sodium retention
C) TZD fluid retention is caused by reduced glomerular filtration from afferent arteriolar constriction
D) TZD fluid retention results from PPAR-gamma-mediated upregulation of the epithelial sodium channel (ENaC) in the collecting duct, and is independent of aldosterone and blood pressure
E) TZD fluid retention is mediated by stimulation of antidiuretic hormone release from the posterior pituitary
ANSWER: D
Rationale:
TZD fluid retention arises from PPAR-gamma (peroxisome proliferator-activated receptor gamma)-mediated upregulation of the epithelial sodium channel (ENaC) in the renal collecting duct, increasing sodium reabsorption and expanding extracellular volume; critically, this mechanism is independent of aldosterone and blood pressure.
Option A: Option A is incorrect because the effect is explicitly aldosterone-independent and does not act through increased aldosterone secretion.
Option B: Option B is incorrect because the sodium retention is independent of blood pressure rather than driven by a hypertensive rise.
Option C: Option C is incorrect because the mechanism is enhanced distal sodium reabsorption via ENaC, not reduced glomerular filtration from afferent constriction.
Option E: Option E is incorrect because the mechanism is collecting-duct ENaC upregulation, not antidiuretic hormone-mediated water retention.
8. The heart failure hospitalization signal across the DPP-4 (dipeptidyl peptidase-4) inhibitor class is agent-specific rather than uniform. Which statement most precisely discriminates the agents on this point?
A) Saxagliptin and alogliptin are associated with increased heart failure hospitalization, whereas sitagliptin and linagliptin showed no excess heart failure signal in their cardiovascular outcome trials
B) Sitagliptin and linagliptin are associated with increased heart failure hospitalization, whereas saxagliptin showed none
C) All four agents increased heart failure hospitalization to the same degree
D) Linagliptin is the agent most strongly linked to heart failure hospitalization
E) None of the gliptins has ever shown a heart failure hospitalization signal in any outcome trial
ANSWER: A
Rationale:
The heart failure signal is agent-specific: saxagliptin increased heart failure hospitalization in its cardiovascular outcome trial and alogliptin showed a directionally similar signal, whereas sitagliptin and linagliptin showed no excess heart failure signal in their respective outcome trials. Sitagliptin or linagliptin are therefore preferred within the class for patients with heart failure.
Option B: Option B is incorrect because it reverses the data: sitagliptin and linagliptin are the reassuring agents, not the ones carrying the signal.
Option C: Option C is incorrect because the risk is not a uniform class effect of equal degree across all four agents.
Option D: Option D is incorrect because linagliptin showed no excess heart failure signal and is not the agent most strongly linked.
Option E: Option E is incorrect because a heart failure signal clearly was observed, specifically with saxagliptin and alogliptin.
9. The bone fracture liability of thiazolidinediones (TZDs) has a defined mechanism and a characteristic fracture pattern. Which statement is correct?
A) TZDs increase fracture risk by directly chelating calcium in bone matrix
B) TZD fracture risk is confined to vertebral compression fractures in elderly men
C) TZDs reduce fracture risk by promoting osteoblast differentiation
D) Fracture risk is unique to rosiglitazone and not shared by pioglitazone
E) PPAR-gamma activation shifts bone marrow mesenchymal stem cells toward adipocyte rather than osteoblast differentiation, increasing fracture risk preferentially at distal sites in postmenopausal women
ANSWER: E
Rationale:
The mechanism is that PPAR-gamma (peroxisome proliferator-activated receptor gamma) activation in bone marrow mesenchymal stem cells favors adipocyte over osteoblast differentiation and also increases osteoclast activity, reducing bone formation and increasing resorption; the resulting fractures occur preferentially at distal extremity sites (wrist, foot, ankle) in postmenopausal women.
Option A: Option A is incorrect because the mechanism is altered stem-cell differentiation and bone turnover, not direct calcium chelation.
Option B: Option B is incorrect because the characteristic fractures are distal extremity fractures in postmenopausal women, not vertebral compression fractures in men.
Option C: Option C is incorrect because TZDs suppress, rather than promote, osteoblast differentiation and therefore raise fracture risk.
Option D: Option D is incorrect because the fracture liability is a class effect shared by both pioglitazone and rosiglitazone, not unique to rosiglitazone.
10. Troglitazone was withdrawn for hepatotoxicity that pioglitazone and rosiglitazone do not share. Which statement most precisely characterizes the nature of that toxicity?
A) It was a predictable, dose-related transaminase elevation detectable in pre-approval trials
B) It resulted from PPAR-gamma activation, a property troglitazone uniquely possessed
C) Troglitazone's tocopherol (vitamin E) moiety is metabolized to a reactive quinone, producing idiosyncratic hepatotoxicity that is not dose-related at therapeutic doses
D) It was caused by renal accumulation of an unmetabolized parent compound
E) The toxicity affected roughly half of all treated patients, making the signal obvious
ANSWER: C
Rationale:
Troglitazone contains a tocopherol (vitamin E, alpha-tocopherol) moiety that undergoes oxidative metabolism to a reactive quinone intermediate, producing idiosyncratic hepatotoxicity that is not dose-related at therapeutic doses and affected only about 1 in 50,000 patients; pioglitazone and rosiglitazone lack this moiety and do not generate the toxic metabolite.
Option A: Option A is incorrect because the toxicity was idiosyncratic and not a predictable dose-related effect, which is precisely why pre-approval trials missed it.
Option B: Option B is incorrect because PPAR-gamma (peroxisome proliferator-activated receptor gamma) activation is shared by all TZDs and is not the basis of the hepatotoxicity.
Option D: Option D is incorrect because the mechanism is a reactive hepatic metabolite, not renal accumulation of unmetabolized parent drug.
Option E: Option E is incorrect because the injury was rare (roughly 1 in 50,000), not an effect seen in half of treated patients.
11. The DPP-4 (dipeptidyl peptidase-4) inhibitors differ in elimination route, which determines their renal dosing. Which statement correctly discriminates the class?
A) Linagliptin is eliminated primarily by biliary/fecal excretion of unchanged drug and requires no renal dose adjustment, whereas sitagliptin, saxagliptin, and alogliptin are primarily renally excreted and require dose adjustment as eGFR falls
B) Linagliptin is the gliptin requiring the most aggressive renal dose reduction
C) Sitagliptin is eliminated almost entirely by the biliary route and needs no renal adjustment
D) All gliptins are eliminated identically by hepatic metabolism with no renal component
E) Saxagliptin requires no renal dose adjustment at any level of kidney function
ANSWER: A
Rationale:
Linagliptin is eliminated primarily by biliary and fecal excretion of unchanged drug, so it requires no renal dose adjustment at any level of kidney function, whereas sitagliptin, saxagliptin, and alogliptin are primarily renally excreted and require progressive dose reduction as the estimated glomerular filtration rate (eGFR) declines.
Option B: Option B is incorrect because linagliptin is the agent that needs no renal adjustment, not the most aggressive reduction.
Option C: Option C is incorrect because sitagliptin is primarily renally excreted and does require renal dose adjustment; it is not a biliary-eliminated agent.
Option D: Option D is incorrect because the gliptins are not all hepatically eliminated without a renal component; three of them are renally cleared.
Option E: Option E is incorrect because saxagliptin is renally excreted and requires dose reduction at lower eGFR, so it does not avoid renal adjustment.
12. Which statement most precisely characterizes the glycemic efficacy and target of alpha-glucosidase inhibitors (AGIs)?
A) AGIs produce the largest HbA1c reduction of any oral class, exceeding metformin
B) AGIs lower fasting glucose substantially while having no effect on postprandial glucose
C) AGIs lower HbA1c by 2 to 3 percent and primarily target fasting hyperglycemia
D) AGIs have no measurable effect on either fasting or postprandial glucose
E) AGIs produce a modest HbA1c reduction (approximately 0.5 to 1.0 percent) and preferentially attenuate postprandial rather than fasting glucose
ANSWER: E
Rationale:
Alpha-glucosidase inhibitors produce a modest HbA1c reduction of approximately 0.5 to 1.0 percent, lower than sulfonylureas, metformin, or DPP-4 (dipeptidyl peptidase-4) inhibitors, and they preferentially attenuate postprandial glucose excursions by slowing intestinal carbohydrate digestion, with little effect on fasting glucose.
Option A: Option A is incorrect because AGI efficacy is modest, not the largest of any oral class.
Option B: Option B is incorrect because AGIs primarily blunt postprandial rather than fasting glucose, which is the reverse of the claim.
Option C: Option C is incorrect because the HbA1c reduction is modest (0.5 to 1.0 percent), not 2 to 3 percent, and the target is postprandial, not fasting, glucose.
Option D: Option D is incorrect because AGIs clearly do reduce postprandial glucose, so the claim of no measurable effect is wrong.
13. Beyond the incretin hormones, the DPP-4 (dipeptidyl peptidase-4) enzyme cleaves several other endogenous substrates. Which statement correctly identifies these additional substrates and their relevance?
A) DPP-4 cleaves only GLP-1 and GIP and has no other endogenous substrates
B) DPP-4 cleaves insulin and glucagon directly, accounting for its glycemic effect
C) DPP-4 also cleaves substrates such as stromal cell-derived factor-1 (SDF-1), BNP (B-type natriuretic peptide), neuropeptide Y, and substance P, and altered handling of these may contribute to off-target effects
D) DPP-4 cleaves albumin, explaining the fluid retention seen with gliptins
E) DPP-4 acts only on intracellular signaling proteins and not on circulating peptides
ANSWER: C
Rationale:
In addition to the incretins, DPP-4 (dipeptidyl peptidase-4) cleaves multiple endogenous substrates including stromal cell-derived factor-1 (SDF-1/CXCL12), BNP (B-type natriuretic peptide), neuropeptide Y, and substance P; altered handling of substrates such as SDF-1 and BNP is among the proposed explanations for off-target effects, including the heart failure signal seen with some agents.
Option A: Option A is incorrect because DPP-4 has many substrates beyond GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
Option B: Option B is incorrect because DPP-4 does not directly cleave insulin and glucagon to produce its glycemic effect; that effect is incretin-mediated.
Option D: Option D is incorrect because DPP-4 does not cleave albumin, and gliptins are weight-neutral without the fluid retention characteristic of TZDs.
Option E: Option E is incorrect because DPP-4 acts on circulating peptide substrates, not solely on intracellular signaling proteins.
14. A specific safety caution applies to pioglitazone that does not apply equally across all oral antidiabetic agents. Which statement correctly identifies it?
A) Pioglitazone is associated with an increased risk of medullary thyroid carcinoma and is contraindicated with a family history of it
B) Pioglitazone carries a bladder cancer caution and should be avoided in patients with active bladder cancer or uninvestigated hematuria
C) Pioglitazone is contraindicated in all patients over age 50 because of universally proven malignancy risk
D) Pioglitazone is associated with colorectal cancer and requires annual colonoscopy in all users
E) Pioglitazone has no agent-specific malignancy caution of any kind
ANSWER: B
Rationale:
Pioglitazone carries an agent-specific bladder cancer caution: observational data raised a modest signal, prompting a label warning, and current consensus is to avoid pioglitazone in patients with active bladder cancer or uninvestigated hematuria and to use caution with a prior history of bladder cancer.
Option A: Option A is incorrect because medullary thyroid carcinoma caution is associated with GLP-1 (glucagon-like peptide-1) receptor agonists, not with pioglitazone.
Option C: Option C is incorrect because pioglitazone is not contraindicated in all patients over 50; the malignancy signal is modest and situation-specific, not a universal age-based contraindication.
Option D: Option D is incorrect because the relevant signal concerns bladder cancer, not colorectal cancer, and routine colonoscopy is not a pioglitazone requirement.
Option E: Option E is incorrect because pioglitazone does have a specific bladder cancer caution, so denying any caution is wrong.
15. Which statement most precisely reflects the current evidence status of the pancreatitis concern with incretin-based therapies (DPP-4 inhibitors and GLP-1 receptor agonists)?
A) Pancreatitis is a confirmed, statistically significant class-level hazard that mandates avoidance of all incretin therapies
B) Pancreatitis risk has been definitively disproven, and the precaution has been removed from all labeling
C) Pancreatitis risk applies only to GLP-1 receptor agonists and has never been associated with DPP-4 inhibitors
D) Pooled cardiovascular outcome trial data did not confirm a statistically significant increase in confirmed acute pancreatitis, so it remains a listed precaution rather than a proven class hazard
E) The pancreatitis signal was confirmed only in trials enrolling fewer than 1,000 patients and never examined in larger studies
ANSWER: D
Rationale:
The large dedicated cardiovascular outcome trials, pooled across more than 45,000 patients, did not confirm a statistically significant increase in confirmed acute pancreatitis with DPP-4 (dipeptidyl peptidase-4) inhibitors or liraglutide versus placebo; regulators concluded pancreatitis is not a proven class-level hazard, though it remains a listed precaution given mechanistic plausibility.
Option A: Option A is incorrect because the data did not confirm a significant class-level hazard mandating avoidance.
Option B: Option B is incorrect because the risk has not been formally disproven and the precaution remains in labeling.
Option C: Option C is incorrect because the pancreatitis concern was examined for DPP-4 inhibitors as well, not exclusively for GLP-1 (glucagon-like peptide-1) receptor agonists.
Option E: Option E is incorrect because the question was specifically studied in very large outcome trials, not confined to small studies under 1,000 patients.
16. The low hypoglycemia risk of DPP-4 (dipeptidyl peptidase-4) inhibitor monotherapy reflects a specific mechanistic feature. Which statement correctly identifies that feature and the consequence of combining a gliptin with a sulfonylurea?
A) The low hypoglycemia risk reflects glucose-dependent insulin secretion that ceases as glucose normalizes; adding a sulfonylurea introduces non-glucose-dependent secretion and removes that safety feature
B) The low hypoglycemia risk reflects rapid drug elimination, and adding a sulfonylurea has no effect on hypoglycemia risk
C) Gliptins suppress insulin secretion entirely, and combining with a sulfonylurea restores normal secretion without hypoglycemia
D) The glucose-dependence of gliptins is preserved even when a sulfonylurea is added, so the combination carries no added hypoglycemia risk
E) Sulfonylureas are also glucose-dependent secretagogues, so combining them with gliptins cannot increase hypoglycemia risk
ANSWER: A
Rationale:
The low monotherapy hypoglycemia risk of gliptins reflects glucose-dependent incretin-mediated insulin secretion that is extinguished as glucose normalizes; adding a sulfonylurea introduces non-glucose-dependent insulin secretion, which removes the glucose-dependence safety feature and is why the combination requires hypoglycemia precautions.
Option B: Option B is incorrect because the safety feature is glucose-dependence, not rapid elimination, and adding a sulfonylurea does raise hypoglycemia risk.
Option C: Option C is incorrect because gliptins enhance rather than suppress insulin secretion.
Option D: Option D is incorrect because the gliptin's glucose-dependence does not protect against sulfonylurea-driven secretion; the added secretagogue itself is not glucose-dependent.
Option E: Option E is incorrect because sulfonylureas are not glucose-dependent secretagogues, so the combination can indeed increase hypoglycemia risk.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.